{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:23:13Z","timestamp":1792167793889,"version":"4.4.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bavarian Center for Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite advances in multimodal therapy, survival in advanced head and neck squamous cell carcinoma (HNSCC) has improved only modestly. Tumor-informed circulating tumor DNA (ctDNA) assays allow early detection of molecular residual disease (MRD) and recurrence after curative treatment. We analyzed ctDNA in plasma from 76 and saliva from 54 HNSCC patients before and after curative-intent surgery, testing 656 plasma and 128 saliva samples longitudinally. High preoperative ctDNA shedding correlated with advanced pathological stage, lymph node involvement, adverse histologic features, and molecular markers including PD-1 expression and tumor mutational burden. Transcriptomic profiling showed associations between high shedding and increased proliferation, EGFR\/MAPK pathway activity, and upregulation of EGFR-related invasion and metastasis genes. Plasma ctDNA detected \u226514 days post-surgery identified 91.3% of recurrences, with lead times up to 500 days before clinical confirmation. These results highlight the value of serial ctDNA monitoring for early relapse detection and potentially improved treatment guidance in HNSCC.<\/jats:p>","DOI":"10.1038\/s41698-026-01309-0","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T06:35:42Z","timestamp":1770100542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-3706","authenticated-orcid":false,"given":"Susanne","family":"Flach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulos","family":"Pipinikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Huberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clodagh","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marsico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Jurmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"St\u00f6cklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Abaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitzan","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph A.","family":"Reichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Canis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"1309_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrc.2018.11","volume":"18","author":"CR Leemans","year":"2018","unstructured":"Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck cancer. Nat. Rev. Cancer 18, 269\u2013282 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1309_CR2","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"JP Machiels","year":"2020","unstructured":"Machiels, J. P. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1462\u20131475 (2020).","journal-title":"Ann. Oncol."},{"key":"1309_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","volume":"8","author":"Q Li","year":"2023","unstructured":"Li, Q., Tie, Y., Alu, A., Ma, X. & Shi, H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct. Target Ther. 8, 31 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1309_CR4","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.ejca.2015.07.043","volume":"51","author":"G Gatta","year":"2015","unstructured":"Gatta, G. et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study. Eur. J. Cancer 51, 2130\u20132143 (2015).","journal-title":"Eur. J. Cancer"},{"key":"1309_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0194-59980300476-5","volume":"129","author":"P Vaamonde","year":"2003","unstructured":"Vaamonde, P., Mart\u00edn, C., del R\u00edo, M. & LaBella, T. Second primary malignancies in patients with cancer of the head and neck. Otolaryngol.-Head. Neck Surg. 129, 65\u201370 (2003).","journal-title":"Otolaryngol.-Head. Neck Surg."},{"key":"1309_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.semcancer.2004.08.004","volume":"15","author":"BJM Braakhuis","year":"2005","unstructured":"Braakhuis, B. J. M., Leemans, C. R. & Brakenhoff, R. H. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin. Cancer Biol. 15, 113\u2013120 (2005).","journal-title":"Semin. Cancer Biol."},{"key":"1309_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S1470-2045(23)00538-7","volume":"25","author":"TK Kjaer","year":"2023","unstructured":"Kjaer, T. K. et al. Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study. Lancet Oncol. 25, 126\u2013136 (2023).","journal-title":"Lancet Oncol."},{"key":"1309_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/hed.26898","volume":"44","author":"MG Bulbul","year":"2022","unstructured":"Bulbul, M. G. et al. Salvage surgery for recurrent squamous cell carcinoma of the head and neck: systematic review and meta-analysis. Head. Neck 44, 275\u2013285 (2022).","journal-title":"Head. Neck"},{"key":"1309_CR9","doi-asserted-by":"publisher","first-page":"55600","DOI":"10.18632\/oncotarget.16340","volume":"8","author":"JH Chang","year":"2017","unstructured":"Chang, J. H., Wu, C. C., Yuan, K. S. P., Wu, A. T. H. & Wu, S. Y. Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. Oncotarget 8, 55600\u201355612 (2017).","journal-title":"Oncotarget"},{"key":"1309_CR10","doi-asserted-by":"publisher","first-page":"djaf128","DOI":"10.1093\/jnci\/djaf128","volume":"117","author":"A Williamson","year":"2025","unstructured":"Williamson, A. et al. Multidisciplinary evidence-based consensus statements on salvage surgery for recurrent head and neck cancer (International Centre for Recurrent head and neck Cancer). J. Natl. Cancer Inst. 117, djaf128 (2025).","journal-title":"J. Natl. Cancer Inst."},{"key":"1309_CR11","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/lary.23341","volume":"122","author":"DM Beswick","year":"2012","unstructured":"Beswick, D. M., Gooding, W. E., Johnson, J. T. & Branstetter, B. F. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography\/computed tomography monitoring. Laryngoscope 122, 1512\u20131517 (2012).","journal-title":"Laryngoscope"},{"key":"1309_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.oraloncology.2018.11.022","volume":"88","author":"DA Silverman","year":"2019","unstructured":"Silverman, D. A., Puram, S. V., Rocco, J. W., Old, M. O. & Kang, S. Y. Salvage laryngectomy following organ-preservation therapy \u2013 An evidence-based review. Oral. Oncol. 88, 137\u2013144 (2019).","journal-title":"Oral. Oncol."},{"key":"1309_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00000421-200104000-00004","volume":"24","author":"SP Reddy","year":"2001","unstructured":"Reddy, S. P. et al. Stomal recurrence in patients with T1 glottic cancer after salvage laryngectomy for radiotherapy failures: role of p53 overexpression and subglottic extension. Am. J. Clin. Oncol. 24, 124\u2013127 (2001).","journal-title":"Am. J. Clin. Oncol."},{"key":"1309_CR14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.clon.2010.05.016","volume":"22","author":"CJ Flynn","year":"2010","unstructured":"Flynn, C. J. et al. The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer. Clin. Oncol. 22, 868\u2013873 (2010).","journal-title":"Clin. Oncol."},{"key":"1309_CR15","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/1078-0432.CCR-22-0562","volume":"28","author":"BM Berger","year":"2022","unstructured":"Berger, B. M. et al. Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin. Cancer Res. 28, 4292\u20134301 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR16","doi-asserted-by":"publisher","first-page":"0716","DOI":"10.1158\/2159-8290.CD-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri, A. A. et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 7, 0716 (2017).","journal-title":"Cancer Discov."},{"key":"1309_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","volume":"33","author":"D Gale","year":"2022","unstructured":"Gale, D. et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann. Oncol. 33, 500\u2013510 (2022).","journal-title":"Ann. Oncol."},{"key":"1309_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 616, 553\u2013562 (2023).","journal-title":"Nature"},{"key":"1309_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","volume":"31","author":"JRM Black","year":"2025","unstructured":"Black, J. R. M. et al. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nat. Med. 31, 70\u201376 (2025).","journal-title":"Nat. Med."},{"key":"1309_CR20","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"1309_CR21","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92\u2013346ra92 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1309_CR22","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie, J. et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5, 1710\u20131717 (2019).","journal-title":"JAMA Oncol."},{"key":"1309_CR23","first-page":"1509","volume":"31","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. New Engl. J. Med. 31, 1509\u20131518 (2022).","journal-title":"New Engl. J. Med."},{"key":"1309_CR24","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat. Med. 31, 1509\u20131518 (2025).","journal-title":"Nat. Med."},{"key":"1309_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med 29, 127\u2013134 (2023).","journal-title":"Nat. Med"},{"key":"1309_CR26","doi-asserted-by":"publisher","first-page":"18.02052","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 18.02052 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1309_CR27","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","volume":"158","author":"TD Azad","year":"2020","unstructured":"Azad, T. D. et al. Circulating tumor DNA Analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 158, 494\u2013505.e6 (2020).","journal-title":"Gastroenterology"},{"key":"1309_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 11, 346 (2020).","journal-title":"Cell Death Dis."},{"key":"1309_CR29","doi-asserted-by":"publisher","first-page":"103978","DOI":"10.1016\/j.esmoop.2024.103978","volume":"9","author":"S Genta","year":"2024","unstructured":"Genta, S. et al. Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open 9, 103978 (2024).","journal-title":"ESMO Open"},{"key":"1309_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"SJ Dawson","year":"2013","unstructured":"Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199\u20131209 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1309_CR31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.15252\/emmm.201404913","volume":"7","author":"E Olsson","year":"2015","unstructured":"Olsson, E. et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 7, 1034\u20131047 (2015).","journal-title":"EMBO Mol. Med."},{"key":"1309_CR32","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med 7, 302ra133 (2015).","journal-title":"Sci. Transl. Med"},{"key":"1309_CR33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","volume":"5","author":"I Garcia-Murillas","year":"2019","unstructured":"Garcia-Murillas, I. et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5, 1473\u20131478 (2019).","journal-title":"JAMA Oncol."},{"key":"1309_CR34","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes, R. C. et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin. Cancer Res. 25, 4255\u20134263 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR35","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","volume":"26","author":"Parsons, H. A","year":"2020","unstructured":"Parsons, H. A. et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin. Cancer Res. 26, 2556\u20132564 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR36","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1200\/JCO.22.00908","volume":"40","author":"Lipsyc-Sharf, M","year":"2022","unstructured":"Lipsyc-Sharf, M. et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative breast cancer. J. Clin. Oncol. 40, 2408\u20132419 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1309_CR37","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","volume":"126","author":"S Flach","year":"2022","unstructured":"Flach, S. et al. Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS)\u2014a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Brit. J. Cancer 126, 1186\u20131195 (2022).","journal-title":"Brit. J. Cancer"},{"key":"1309_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41418-024-01272-y","volume":"31","author":"E Sanz-Garcia","year":"2024","unstructured":"Sanz-Garcia, E. et al. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. Cell Death Differ. 31, 460\u2013468 (2024).","journal-title":"Cell Death Differ."},{"key":"1309_CR39","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","volume":"30","author":"GJ Hanna","year":"2024","unstructured":"Hanna, G. J. et al. Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma. Clin. Cancer Res. 30, 3329\u20133336 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamaoto.2023.1937","volume":"149","author":"RM Ferrandino","year":"2023","unstructured":"Ferrandino, R. M. et al. Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus\u2013associated oropharyngeal cancer. JAMA OtolaryngolHead Neck Surg. 149, 971\u2013977 (2023).","journal-title":"JAMA OtolaryngolHead Neck Surg."},{"key":"1309_CR41","doi-asserted-by":"publisher","first-page":"104534","DOI":"10.1016\/j.esmoop.2025.104534","volume":"10","author":"N Honor\u00e9","year":"2025","unstructured":"Honor\u00e9, N. et al. Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN). ESMO Open 10, 104534 (2025).","journal-title":"ESMO Open"},{"key":"1309_CR42","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750\u2013768 (2022).","journal-title":"Ann. Oncol."},{"key":"1309_CR43","doi-asserted-by":"publisher","first-page":"104296","DOI":"10.1016\/j.esmoop.2025.104296","volume":"10","author":"W Janni","year":"2025","unstructured":"Janni, W. et al. Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay. ESMO Open 10, 104296 (2025).","journal-title":"ESMO Open"},{"key":"1309_CR44","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1158\/1078-0432.CCR-25-0307","volume":"31","author":"ES Sim","year":"2025","unstructured":"Sim, E. S. et al. Early postoperative minimal residual disease detection with MAESTRO is associated with recurrence and worse survival in patients with head and neck cancer. Clin. Cancer Res. 31, 3494\u20133502 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1373\/clinchem.2017.285668","volume":"64","author":"MA Schirmer","year":"2018","unstructured":"Schirmer, M. A. et al. Cell-free plasma DNA for disease stratification and prognosis in head and neck cancer. Clin. Chem. 64, 959\u2013970 (2018).","journal-title":"Clin. Chem."},{"key":"1309_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11864-017-0484-y","volume":"18","author":"SH Huang","year":"2017","unstructured":"Huang, S. H. & O\u2019Sullivan, B. Overview of the 8th edition TNM classification for head and neck cancer. Curr. Treat. Options Oncol. 18, 34\u201313 (2017).","journal-title":"Curr. Treat. Options Oncol."},{"key":"1309_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hed.25932","volume":"41","author":"JCH Hsieh","year":"2019","unstructured":"Hsieh, J. C. H. et al. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. Head. Neck 41, 19\u201345 (2019).","journal-title":"Head. Neck"},{"key":"1309_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24\u201335 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1309_CR49","first-page":"122","volume":"67","author":"WM Lydiatt","year":"2017","unstructured":"Lydiatt, W. M. et al. Head and neck cancers\u2014major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 122\u2013137 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"1309_CR50","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. Ca Cancer J. Clin. 67, 93\u201399 (2017).","journal-title":"Ca Cancer J. Clin."},{"key":"1309_CR51","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hed.26016","volume":"42","author":"A Coca-Pelaz","year":"2020","unstructured":"Coca-Pelaz, A. et al. The risk of second primary tumors in head and neck cancer: a systematic review. Head. Neck 42, 456\u2013466 (2020).","journal-title":"Head. Neck"},{"key":"1309_CR52","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3389\/fonc.2019.01275","volume":"9","author":"WL Zhang","year":"2019","unstructured":"Zhang, W. L. et al. Susceptibility of multiple primary cancers in patients with head and neck cancer: nature or nurture? Front. Oncol. 9, 1275 (2019).","journal-title":"Front. Oncol."},{"key":"1309_CR53","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1078-0432.CCR-03-1077","volume":"10","author":"A Argiris","year":"2004","unstructured":"Argiris, A. et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin. Cancer Res. 10, 1956\u20131962 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/0194599813496373","volume":"149","author":"DH Lee","year":"2013","unstructured":"Lee, D. H. et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. OtolaryngolHead Neck Surg. 149, 579\u2013586 (2013).","journal-title":"OtolaryngolHead Neck Surg."},{"key":"1309_CR55","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"1309_CR56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479\u2013491 (2016).","journal-title":"Cancer Discov."},{"key":"1309_CR57","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21053\/ceo.2015.00976","volume":"9","author":"N Denaro","year":"2016","unstructured":"Denaro, N., Merlano, M. C. & Russi, E. G. Follow-up in head and neck cancer: do more does it mean do better? A systematic review and our proposal based on our experience. Clin. Exp. Otorhinolar 9, 287\u2013297 (2016).","journal-title":"Clin. Exp. Otorhinolar"},{"key":"1309_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.oraloncology.2012.03.013","volume":"48","author":"RP Takes","year":"2012","unstructured":"Takes, R. P. et al. Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral. Oncol. 48, 775\u2013779 (2012).","journal-title":"Oral. Oncol."},{"key":"1309_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaw8513","volume":"11","author":"P Jurmeister","year":"2019","unstructured":"Jurmeister, P. et al. Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases. Sci. Transl. Med. 11, 1\u201311 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1309_CR60","doi-asserted-by":"publisher","first-page":"224ra224-224ra2","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224-224ra24 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1309_CR61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548\u2013554 (2014).","journal-title":"Nat. Med."},{"key":"1309_CR62","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2021","unstructured":"Henriksen, T. V. et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin. Cancer Res. 28, 507\u2013517 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR63","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","volume":"32","author":"E Ococks","year":"2020","unstructured":"Ococks, E. et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann. Oncol. 32, 522\u2013532 (2020).","journal-title":"Ann. Oncol."},{"key":"1309_CR64","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee, J. et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat. Med. 28, 2353\u20132363 (2022).","journal-title":"Nat. Med."},{"key":"1309_CR65","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey, A., Church, M., Rothwell, D., Dive, C. & Cook, N. Circulating tumour DNA \u2014 looking beyond the blood. Nat. Rev. Clin. Oncol. 19, 600\u2013612 (2022).","journal-title":"Rev. Clin. Oncol."},{"key":"1309_CR66","doi-asserted-by":"publisher","first-page":"2200261","DOI":"10.1200\/PO.22.00261","volume":"6","author":"H Husain","year":"2022","unstructured":"Husain, H. et al. Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples. JCO Precis. Oncol. 6, 2200261 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"1309_CR67","doi-asserted-by":"publisher","first-page":"107830","DOI":"10.1016\/j.celrep.2020.107830","volume":"31","author":"A Rostami","year":"2020","unstructured":"Rostami, A. et al. Senescence, necrosis, and apoptosis govern circulating cell-free DNA release kinetics. Cell Rep. 31, 107830 (2020).","journal-title":"Cell Rep."},{"key":"1309_CR68","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ebiom.2019.10.008","volume":"49","author":"AT Madsen","year":"2019","unstructured":"Madsen, A. T., Hojbjerg, J. A., Sorensen, B. S. & Winther-Larsen, A. Day-to-day and within-day biological variation of cell-free DNA. EBioMedicine 49, 284\u2013290 (2019).","journal-title":"EBioMedicine"},{"key":"1309_CR69","doi-asserted-by":"publisher","first-page":"eabi8618","DOI":"10.1126\/sciadv.abi8618","volume":"8","author":"E Sanz-Garcia","year":"2022","unstructured":"Sanz-Garcia, E., Zhao, E., Bratman, S. V. & Siu, L. L. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges. Sci. Adv. 8, eabi8618 (2022).","journal-title":"Sci. Adv."},{"key":"1309_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12967-024-04937-x","volume":"22","author":"JP Rodrigo","year":"2024","unstructured":"Rodrigo, J. P. et al. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis. J. Transl. Med. 22, 135 (2024).","journal-title":"J. Transl. Med."},{"key":"1309_CR71","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.tripleo.2006.09.011","volume":"103","author":"PV Angadi","year":"2007","unstructured":"Angadi, P. V. & Krishnapillai, R. Cyclin D1 expression in oral squamous cell carcinoma and verrucous carcinoma: correlation with histological differentiation. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio. Endodontol. 103, e30\u2013e35 (2007).","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio. Endodontol."},{"key":"1309_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0304-3835(00)00546-2","volume":"160","author":"Y Nakahara","year":"2000","unstructured":"Nakahara, Y. et al. Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett. 160, 3\u20138 (2000).","journal-title":"Cancer Lett."},{"key":"1309_CR73","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1368-8375(99)00093-7","volume":"36","author":"S Koontongkaew","year":"2000","unstructured":"Koontongkaew, S., Chareonkitkajorn, L., Chanvitan, A., Leelakriangsak, M. & Amornphimoltham, P. Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral. Oncol. 36, 334\u2013339 (2000).","journal-title":"Oral. Oncol."},{"key":"1309_CR74","first-page":"2810","volume":"5","author":"RJ Bova","year":"1999","unstructured":"Bova, R. J. et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. J. Am. Assoc. Cancer Res. 5, 2810\u20132819 (1999).","journal-title":"J. Am. Assoc. Cancer Res."},{"key":"1309_CR75","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1158\/1078-0432.1160.11.3","volume":"11","author":"Z Yu","year":"2005","unstructured":"Yu, Z. et al. Cyclin D1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin. Cancer Res 11, 1160\u20131166 (2005).","journal-title":"Clin. Cancer Res"},{"key":"1309_CR76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archotol.1997.01900050045005","volume":"123","author":"Michalides, R. J. A. M","year":"1997","unstructured":"Michalides, R. J. A. M. et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch. OtolaryngolHead Neck Surg. 123, 497\u2013502 (1997).","journal-title":"Arch. OtolaryngolHead Neck Surg."},{"key":"1309_CR77","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cbf.3028","volume":"32","author":"K Asai","year":"2014","unstructured":"Asai, K., Funaba, M. & Murakami, M. Enhancement of RANKL-induced MITF-E expression and osteoclastogenesis by TGF-\u03b2. Cell Biochem. Funct. 32, 401\u2013409 (2014).","journal-title":"Cell Biochem. Funct."},{"key":"1309_CR78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12575-018-0073-x","volume":"20","author":"YC Chuang","year":"2018","unstructured":"Chuang, Y. C. et al. Blockade of ITGA2 Induces apoptosis and inhibits cell migration in gastric cancer. Biol. Proced. Online 20, 10 (2018).","journal-title":"Biol. Proced. Online"},{"key":"1309_CR79","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.18632\/oncotarget.3148","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC). Oncotarget 6, 7454\u20137469 (2015).","journal-title":"Oncotarget"},{"key":"1309_CR80","first-page":"73","volume":"41","author":"H Cai","year":"2022","unstructured":"Cai, H. et al. Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor \u03b2 pathway in pancreatic cancer via the TFCP2-SMAD2 axis. J. Exp. Clin. Cancer Res. CR 41, 73 (2022).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"1309_CR81","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-025-02290-1","volume":"24","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer. Mol. Cancer 24, 94 (2025).","journal-title":"Mol. Cancer"},{"key":"1309_CR82","doi-asserted-by":"publisher","first-page":"104458","DOI":"10.1016\/j.oraloncology.2019.104458","volume":"99","author":"AS Parikh","year":"2019","unstructured":"Parikh, A. S. et al. Immunohistochemical quantification of partial-EMT in oral cavity squamous cell carcinoma primary tumors is associated with nodal metastasis. Oral. Oncol. 99, 104458 (2019).","journal-title":"Oral. Oncol."},{"key":"1309_CR83","doi-asserted-by":"publisher","first-page":"e1-1611","DOI":"10.1016\/j.cell.2017.10.044","volume":"171","author":"SV Puram","year":"2017","unstructured":"Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, e1-1611\u2013e1-16124 (2017).","journal-title":"Cell"},{"key":"1309_CR84","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12943-022-01646-1","volume":"21","author":"H Schinke","year":"2022","unstructured":"Schinke, H. et al. A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer. Mol. Cancer 21, 178 (2022).","journal-title":"Mol. Cancer"},{"key":"1309_CR85","doi-asserted-by":"publisher","first-page":"114186","DOI":"10.1016\/j.ejca.2024.114186","volume":"207","author":"L Andersen","year":"2024","unstructured":"Andersen, L. et al. Exploring the biology of ctDNA release in colorectal cancer. Eur. J. Cancer 207, 114186 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1309_CR86","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","volume":"22","author":"K Pantel","year":"2024","unstructured":"Pantel, K. & Alix-Panabi\u00e8res, C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat. Rev. Clin. Oncol. 22, 65\u201377 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1309_CR87","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s41416-024-02867-5","volume":"131","author":"N \u00d8gaard","year":"2024","unstructured":"\u00d8gaard, N. et al. Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer. Br. J. Cancer 131, 1705\u20131717 (2024).","journal-title":"Br. J. Cancer"},{"key":"1309_CR88","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.6004\/jnccn.2014.0142","volume":"12","author":"DG Pfister","year":"2014","unstructured":"Pfister, D. G. et al. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw: JNCCN 12, 1454\u20131487 (2014).","journal-title":"J. Natl. Compr. Cancer Netw: JNCCN"},{"key":"1309_CR89","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/PAI.0b013e3181ecaf1c","volume":"19","author":"TC Pereira","year":"2010","unstructured":"Pereira, T. C., Share, S. M., Magalh\u00e3es, A. V. & Silverman, J. F. Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohistochemical tissue microarray study of 194 cases. Appl Immunohistochem. Mol. Morphol: Aimm. 19, 10\u201314 (2010).","journal-title":"Appl Immunohistochem. Mol. Morphol: Aimm."},{"key":"1309_CR90","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41698-025-01084-4","volume":"9","author":"DA Ruiz-Torres","year":"2025","unstructured":"Ruiz-Torres, D. A. et al. Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent\/metastatic head and neck cancer. npj Precis Oncol. 9, 298 (2025).","journal-title":"npj Precis Oncol."},{"key":"1309_CR91","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen, T. V. et al. Circulating tumor DNA in Stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin. Cancer Res. 28, 507\u2013517 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR92","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/1878-0261.12729","volume":"14","author":"TV Henriksen","year":"2020","unstructured":"Henriksen, T. V. et al. The effect of surgical trauma on circulating free DNA levels in cancer patients\u2014implications for studies of circulating tumor DNA. Mol. Oncol. 14, 1670\u20131679 (2020).","journal-title":"Mol. Oncol."},{"key":"1309_CR93","doi-asserted-by":"publisher","first-page":"105904","DOI":"10.1016\/j.esmoop.2025.105904","volume":"10","author":"G Bruixola","year":"2025","unstructured":"Bruixola, G. et al. Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer. ESMO Open 10, 105904 (2025).","journal-title":"ESMO Open"},{"key":"1309_CR94","doi-asserted-by":"publisher","first-page":"200","DOI":"10.18632\/oncotarget.28565","volume":"15","author":"J Northcott","year":"2024","unstructured":"Northcott, J. et al. Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay. Oncotarget 15, 200\u2013218 (2024).","journal-title":"Oncotarget"},{"key":"1309_CR95","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ccell.2025.09.006","volume":"43","author":"WHA Tsui","year":"2025","unstructured":"Tsui, W. H. A., Jiang, P. & Lo, Y. M. D. Cell-free DNA fragmentomics in cancer. Cancer Cell 43, 1792\u20131814 (2025).","journal-title":"Cancer Cell"},{"key":"1309_CR96","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.annonc.2024.08.2348","volume":"36","author":"G Liu","year":"2024","unstructured":"Liu, G. et al. Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies. Ann. Oncol. 36, 108\u2013117 (2024).","journal-title":"Ann. Oncol."},{"key":"1309_CR97","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/s41467-024-47886-1","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions. Nat. Commun. 15, 3700 (2024).","journal-title":"Nat. Commun."},{"key":"1309_CR98","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-21-0110","volume":"27","author":"JM Burgener","year":"2021","unstructured":"Burgener, J. M. et al. Tumor-naive multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma. Clin. Cancer Res. 27, 4230\u20134244 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1309_CR99","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/jamaoncol.2023.0425","volume":"9","author":"S Mo","year":"2023","unstructured":"Mo, S. et al. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA Oncol. 9, 770\u2013778 (2023).","journal-title":"JAMA Oncol."},{"key":"1309_CR100","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2025.02.002","volume":"43","author":"WKJ Lam","year":"2025","unstructured":"Lam, W. K. J. et al. Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma. Cancer Cell 43, 728\u2013739 (2025).","journal-title":"Cancer Cell"},{"key":"1309_CR101","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","volume":"333","author":"N Stransky","year":"2011","unstructured":"Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157\u20131160 (2011).","journal-title":"Science"},{"key":"1309_CR102","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nyas.12599","volume":"1333","author":"W Sun","year":"2014","unstructured":"Sun, W. & Califano, J. A. Sequencing the head and neck cancer genome: implications for therapy. Ann. N. Y. Acad. Sci. 1333, 33\u201342 (2014).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1309_CR103","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"TCGA Network","year":"2015","unstructured":"Network, TCGA. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576\u2013582 (2015).","journal-title":"Nature"},{"key":"1309_CR104","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","volume":"29","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat. Med. 29, 588\u2013592 (2023).","journal-title":"Nat. Med."},{"key":"1309_CR105","doi-asserted-by":"crossref","unstructured":"Pagel, K. A. et al. OpenCRAVAT, an open source collaborative platform for the annotation of human genetic variation. bioRxiv. 10, 794297 (2019).","DOI":"10.1101\/794297"},{"key":"1309_CR106","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46 (Database issue):gkx1153-.(2024)."},{"key":"1309_CR107","doi-asserted-by":"publisher","first-page":"eadg7492","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).","journal-title":"Science"},{"key":"1309_CR108","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/bioinformatics\/btr671","volume":"30","author":"Y Xiao","year":"2014","unstructured":"Xiao, Y. et al. A novel significance score for gene selection and ranking. Bioinformatics 30, 801\u2013807 (2014).","journal-title":"Bioinformatics"},{"key":"1309_CR109","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","volume":"14","author":"J Reimand","year":"2019","unstructured":"Reimand, J. et al. Pathway enrichment analysis and visualization of omics data using g: profiler, GSEA, Cytoscape and EnrichmentMap. Nat. Protoc. 14, 482\u2013517 (2019).","journal-title":"Nat. Protoc."},{"key":"1309_CR110","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1093\/nar\/gkad841","volume":"51","author":"S M\u00fcller-Dott","year":"2023","unstructured":"M\u00fcller-Dott, S. et al. Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities. Nucleic Acids Res. 51, 10934\u201310949 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1309_CR111","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","volume":"232","author":"J Galon","year":"2014","unstructured":"Galon, J. et al. Towards the introduction of the \u2018Immunoscore\u2019 in the classification of malignant tumours. J. Pathol. 232, 199\u2013209 (2014).","journal-title":"J. Pathol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01309-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:03:20Z","timestamp":1772813000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01309-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1309"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01309-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.P., C.M., and G.M. are employees of NeoGenomics Inc. K.H. was an employee of NeoGenomics Inc. at the time the work was conducted and was subsequently an employee and shareholder of SAGA Diagnostics Inc. N.R. is co-inventor on patent applications that have been filed by CRUK or are under consideration for filing by CRUK, that relate to methods for analysis of cell-free DNA for cancer diagnostics. These patents, patent applications and related IP are managed by CRUK in coordination with the host institution. L.K. receives unrestricted research grant (NCT05027165) from AstraZeneca, grants from AMGEN, and Art Tempi (MasterClass LucaNext 2023\/2024); payment from German Cancer Society (for lecturing), AstraZeneca (for lecturing), and Art Tempi; and gets support for attending meetings from AstraZeneca and ELCC. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}